Remimazolam for anesthesia in cardiac and noncardiac surgery. A narrative literature review and synthesis
Study context
- Population
- Cardiac and noncardiac perioperative surgical contexts
- Exposure
- Remimazolam vs widely used agents such as propofol
Methodological detailssystematic search of PubMed/MEDLINE, EMBASE and Google Scholar, studies published 2020–2024, emphasis on RCTs and observational studies
- Systematic search of PubMed/MEDLINE, EMBASE and Google Scholar
- Studies published 2020–2024
- Emphasis on RCTs and observational studies
Main finding
As reported in the abstract
- Growing evidence highlights benefits of remimazolam vs widely used agents such as propofol: superior hemodynamic stability, rapid emergence from anesthesia, minimal respiratory depression
- Benefits demonstrated across various surgical contexts and patient populations
- Existing studies have limitations that challenge the generalizability of these findings
Observational data: associations, not effects.
Original publication
Remimazolam for anesthesia in cardiac and noncardiac surgery. A narrative literature review and synthesis. Anaesth Crit Care Pain Med. Published 27 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →